WO2000071573A3 - Immunogenic peptides derived from mage and the use thereof - Google Patents

Immunogenic peptides derived from mage and the use thereof Download PDF

Info

Publication number
WO2000071573A3
WO2000071573A3 PCT/EP2000/004465 EP0004465W WO0071573A3 WO 2000071573 A3 WO2000071573 A3 WO 2000071573A3 EP 0004465 W EP0004465 W EP 0004465W WO 0071573 A3 WO0071573 A3 WO 0071573A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides derived
mage
immunogenic peptides
tumors
inducing
Prior art date
Application number
PCT/EP2000/004465
Other languages
French (fr)
Other versions
WO2000071573A2 (en
Inventor
Catia Traversari
Silvia Tanzarella
Claudio Bordignon
Original Assignee
Genera Spa
Catia Traversari
Silvia Tanzarella
Claudio Bordignon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Spa, Catia Traversari, Silvia Tanzarella, Claudio Bordignon filed Critical Genera Spa
Priority to EP00935053A priority Critical patent/EP1179019A2/en
Priority to AU50676/00A priority patent/AU777474B2/en
Priority to IL14660500A priority patent/IL146605A0/en
Priority to KR1020017014828A priority patent/KR20020011418A/en
Priority to CA002374354A priority patent/CA2374354A1/en
Priority to JP2000619828A priority patent/JP2003502026A/en
Publication of WO2000071573A2 publication Critical patent/WO2000071573A2/en
Publication of WO2000071573A3 publication Critical patent/WO2000071573A3/en
Priority to HK02108670.8A priority patent/HK1047116A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Abstract

Peptides derived from proteins of the MAGE family and the use thereof as immunogenic agents in the treatment of tumors, the compositions containing them, a method for inducing a cytotoxic response against tumor cells, a melanoma cell line not expressing histocompatibility antigens and the applications thereof.
PCT/EP2000/004465 1999-05-21 2000-05-17 Immunogenic peptides derived from mage and the use thereof WO2000071573A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00935053A EP1179019A2 (en) 1999-05-21 2000-05-17 Immunogenic peptides derived from mage and the use thereof
AU50676/00A AU777474B2 (en) 1999-05-21 2000-05-17 Immunogenic peptides and the use thereof
IL14660500A IL146605A0 (en) 1999-05-21 2000-05-17 Immunogenic peptides derived from mage and the use thereof
KR1020017014828A KR20020011418A (en) 1999-05-21 2000-05-17 Immunogenic peptides derived from MAGE and the use thereof
CA002374354A CA2374354A1 (en) 1999-05-21 2000-05-17 Immunogenic peptides derived from mage and the use thereof
JP2000619828A JP2003502026A (en) 1999-05-21 2000-05-17 MAGE-derived immunogenic peptides and uses thereof
HK02108670.8A HK1047116A1 (en) 1999-05-21 2002-11-29 Immunogenic peptides and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI99A001121 1999-05-21
IT1999MI001121A IT1312568B1 (en) 1999-05-21 1999-05-21 IMMUNOGENIC PEPTIDES AND THEIR USE.

Publications (2)

Publication Number Publication Date
WO2000071573A2 WO2000071573A2 (en) 2000-11-30
WO2000071573A3 true WO2000071573A3 (en) 2001-04-05

Family

ID=11383013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/004465 WO2000071573A2 (en) 1999-05-21 2000-05-17 Immunogenic peptides derived from mage and the use thereof

Country Status (10)

Country Link
EP (1) EP1179019A2 (en)
JP (1) JP2003502026A (en)
KR (1) KR20020011418A (en)
CN (1) CN1227264C (en)
AU (1) AU777474B2 (en)
CA (1) CA2374354A1 (en)
HK (1) HK1047116A1 (en)
IL (1) IL146605A0 (en)
IT (1) IT1312568B1 (en)
WO (1) WO2000071573A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023031A1 (en) * 1993-03-26 1994-10-13 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
WO1995019783A1 (en) * 1994-01-25 1995-07-27 Cytel Corporation Induction of anti-tumor cytotoxic t lymphocytes in humans using synthetic peptide epitopes
WO1999014326A1 (en) * 1997-09-12 1999-03-25 Ludwig Institute For Cancer Research Mage-3 peptides presented by hla class ii molecules
WO2000020581A1 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Mage-a3 peptides presented by hla class ii molecules

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026221A1 (en) * 1998-10-29 2000-05-11 The Dow Chemical Company Preparation of titanium(ii) or zirconium(ii) complexes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023031A1 (en) * 1993-03-26 1994-10-13 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereof
WO1995019783A1 (en) * 1994-01-25 1995-07-27 Cytel Corporation Induction of anti-tumor cytotoxic t lymphocytes in humans using synthetic peptide epitopes
WO1999014326A1 (en) * 1997-09-12 1999-03-25 Ludwig Institute For Cancer Research Mage-3 peptides presented by hla class ii molecules
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
WO2000020581A1 (en) * 1998-10-05 2000-04-13 Ludwig Institute For Cancer Research Mage-a3 peptides presented by hla class ii molecules

Also Published As

Publication number Publication date
EP1179019A2 (en) 2002-02-13
CA2374354A1 (en) 2000-11-30
JP2003502026A (en) 2003-01-21
CN1360595A (en) 2002-07-24
CN1227264C (en) 2005-11-16
KR20020011418A (en) 2002-02-08
AU777474B2 (en) 2004-10-21
HK1047116A1 (en) 2003-02-07
AU5067600A (en) 2000-12-12
WO2000071573A2 (en) 2000-11-30
IL146605A0 (en) 2002-07-25
IT1312568B1 (en) 2002-04-22
ITMI991121A1 (en) 2000-11-21

Similar Documents

Publication Publication Date Title
WO1999058552A3 (en) Peptides that ellicit t, cellular immunity
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
PT1584685E (en) Tumor-associated antigen derivatives from the mage family, used for the preparation of fusion proteins with t-helper epitopes and of compositions for vaccination
AU4612093A (en) Soluble ligands for CD40
AU2001236148A1 (en) Polyorganosilsesquioxane and process for preparing the same
WO2001034801A3 (en) Recombinant gelatin in vaccines
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
AU2001264737A1 (en) Hydrogen storage powder and process for preparing the same
AU5214200A (en) Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
UA85365C2 (en) Cytokine conjugation product for use in cancer therapy
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
AU1227699A (en) Oxyranyle-triazoline thiones and their use as microbicides
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
MXPA02003270A (en) Novel hev antigenic peptide and methods.
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
AU2000275748A1 (en) Hla-a2.1 binding peptides and their uses
WO2004010974A3 (en) Gelatin capsule exhibiting reduced cross-linking

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00809230.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2000 619828

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2374354

Country of ref document: CA

Ref document number: 2374354

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000935053

Country of ref document: EP

Ref document number: 50676/00

Country of ref document: AU

Ref document number: 1020017014828

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020017014828

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000935053

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09979050

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 50676/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020017014828

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2000935053

Country of ref document: EP